StockNews.com Begins Coverage on Trevena (NASDAQ:TRVN)

Stock analysts at StockNews.com began coverage on shares of Trevena (NASDAQ:TRVN) in a research report issued to clients and investors on Thursday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright restated a “neutral” rating and issued a $5.00 target price on shares of Trevena in a research note on Thursday, November 14th.

Trevena Stock Up 12.0 %

Shares of TRVN opened at $1.77 on Thursday. Trevena has a 12 month low of $1.13 and a 12 month high of $17.50. The company’s fifty day moving average is $1.70 and its 200-day moving average is $3.03. The firm has a market cap of $1.52 million, a price-to-earnings ratio of -0.04 and a beta of 1.05.

Trevena (NASDAQ:TRVN) last issued its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($5.79) EPS for the quarter. The company had revenue of $0.28 million during the quarter. As a group, research analysts predict that Trevena will post -23.04 earnings per share for the current fiscal year.

About Trevena

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.